HCV Disease Progression
AASLD 2017: Nivolumab Improves Outcomes in Liver Cancer Study
- Details
- Category: Liver Cancer/HCC
- Published on Thursday, 30 November 2017 00:00
- Written by Liz Highleyman
Nivolumab (Opdivo), a PD-1 checkpoint inhibitor that helps the immune system fight cancer, was associated with a decrease in tumor size or disease stabilization in patients with hepatocellular carcinoma (HCC) in the CheckMate 040 study, according to a report at the 2017 AASLD Liver Meeting last month in Washington, DC.
Coverage of the 2017 AASLD Liver Meeting
- Details
- Category: HBV Treatment
- Published on Thursday, 30 November 2017 00:00
- Written by HIVandHepatitis.com
HIVandHepatitis.com coverage of the 2017 American Association for the Study of Liver Diseases (AASLD) Liver Meeting in Washington, DC, October 20-24, 2017.
Conference highlights include direct-acting antiviral therapy for difficult-to-treat people with hepatitis C, novel hepatitis B agents, complications of viral hepatitis, and NAFLD/NASH.
Full coverage listing by topic
11/30/17
EASL 2017: Hepatitis C Treatment Allows 1 in 4 to Come Off Liver Transplant Waiting List
- Details
- Category: Liver Cancer/HCC
- Published on Monday, 01 May 2017 00:00
- Written by Keith Alcorn
Around a quarter of people with hepatitis C and decompensated cirrhosis came off liver transplant waiting lists in Europe after direct-acting antiviral (DAA) treatment, and very few had any subsequent liver-related problems during 15 months of follow-up, Luca Belli reported on behalf of the ELITA study investigators at the EASL International Liver Congress last month in Amsterdam.
AASLD 2017: Curing Hepatitis C with DAAs Reduces Liver Cancer Risk
- Details
- Category: Liver Cancer/HCC
- Published on Tuesday, 31 October 2017 00:00
- Written by Liz Highleyman
People who achieved a sustained virological response to hepatitis C treatment lowered their risk of hepatocellular carcinoma by around 70%, regardless of whether they were treated with new direct-acting antivirals (DAAs) or older interferon-based therapy, according to study results presented at the 2017 AASLD Liver Meeting last week in Washington, DC.
EASL 2017: Direct-Acting Antivirals for Hepatitis C Not Linked to Higher Liver Cancer Risk
- Details
- Category: HCV Disease Progression
- Published on Thursday, 20 April 2017 00:00
- Written by Liz Highleyman
Hepatitis C patients treated with direct-acting antivirals (DAAs) do not appear to have a higher risk of developing liver cancer compared to those treated with interferon, and the seemingly higher rates seen in some studies are attributable to risk factors such as older age and more advanced liver disease, according to a set of studies presented at the EASL International Liver Congress this week in Amsterdam.
More Articles...
- CROI 2017: Are HIV/HCV Coinfected People Cured with DAAs at Increased Risk for Liver Cancer?
- AASLD 2016: Is DAA Treatment for Hepatitis C Reducing the Need for Liver Transplants?
- AASLD 2016: Curing Hepatitis C Reduces Liver-Related Complications and Death
- AASLD 2016: Liver Cirrhosis and Decompensation on the Rise Among People with Hepatitis C
Web Design and Development by